Tauroursodeoxycholic acid CAS NO (14605-22-2) Available in best price

Comprehensive Overview of Tauroursodeoxycholic Acid (14605-22-2):

Introduction: Tauroursodeoxycholic acid (TUDCA) is a bile acid derivative that occurs naturally in the human body and is also found in the bile of bears and other mammals. It has gained attention in medical research due to its diverse pharmacological properties and potential therapeutic applications in various diseases.

Chemical Structure and Properties: Tauroursodeoxycholic acid (TUDCA) is a conjugate of ursodeoxycholic acid (UDCA) and taurine, a sulfur-containing amino acid. Structurally, it belongs to the bile acid family and is characterized by a steroid nucleus with a hydroxyl group at the C-3 position and a taurine moiety attached to the carboxyl group. TUDCA is a white to off-white crystalline powder with a molecular formula of C26H45NO6S and a molecular weight of approximately 499.7 g/mol.

Physiological Role: Tauroursodeoxycholic acid (TUDCA) plays a crucial role in bile acid metabolism and the regulation of bile flow in the liver and gastrointestinal tract. It helps maintain bile acid homeostasis, solubilize cholesterol, and facilitate the secretion of bile into the small intestine for the digestion and absorption of dietary fats and fat-soluble vitamins. TUDCA also exerts cytoprotective effects on hepatocytes and other cells by modulating cellular stress responses and promoting cell survival pathways.

Pharmacological Effects and Therapeutic Applications:

1. Hepatoprotective Properties: Tauroursodeoxycholic acid (TUDCA) has been extensively studied for its hepatoprotective effects in various liver diseases, including cholestasis, hepatitis, fatty liver disease, and cirrhosis. It helps improve liver function, reduce liver inflammation, and prevent hepatocyte injury by promoting bile flow, inhibiting apoptosis, and modulating inflammatory and fibrotic pathways.
2. Anti-apoptotic Activity: TUDCA exhibits anti-apoptotic effects in different cell types and tissues by inhibiting apoptosis-inducing factors, preventing mitochondrial dysfunction, and modulating intracellular signaling cascades. It may protect against cell death associated with oxidative stress, endoplasmic reticulum (ER) stress, and other pathological conditions.
3. Neuroprotective Effects: Tauroursodeoxycholic acid (TUDCA) has shown neuroprotective properties in preclinical studies and experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). It helps mitigate neuronal damage, reduce neuroinflammation, and improve mitochondrial function, synaptic plasticity, and cognitive function.
4. Metabolic Benefits: TUDCA has been investigated for its potential metabolic effects in obesity, diabetes, and metabolic syndrome. It may improve insulin sensitivity, glucose metabolism, and lipid profiles, as well as reduce adiposity, inflammation, and insulin resistance in metabolic tissues such as the liver, adipose tissue, and skeletal muscle.
5. Gastrointestinal Disorders: Tauroursodeoxycholic acid (TUDCA) has been studied for its therapeutic potential in gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastric mucosal injury. It helps protect the gastrointestinal mucosa, modulate immune responses, and maintain intestinal barrier function.

Clinical Use and Research: Tauroursodeoxycholic acid (TUDCA) is available as a prescription medication in some countries for the treatment of certain liver disorders, particularly cholestatic liver diseases and primary biliary cholangitis (PBC). It is also used off-label in clinical practice and research settings for its potential therapeutic effects in various other diseases and conditions. Clinical trials are ongoing to further investigate the efficacy, safety, and optimal dosage regimens of TUDCA in different patient populations and disease settings.

Safety Considerations: Tauroursodeoxycholic acid (TUDCA) is generally well-tolerated when used at therapeutic doses under medical supervision. However, adverse effects such as gastrointestinal disturbances, including diarrhea and abdominal discomfort, may occur in some individuals, particularly with high doses or prolonged use. Pregnant and breastfeeding women, as well as individuals with pre-existing medical conditions or those taking medications, should consult healthcare professionals before using TUDCA.

Conclusion: Tauroursodeoxycholic acid (TUDCA) is a bile acid derivative with diverse pharmacological properties and potential therapeutic applications in liver diseases, neurodegenerative disorders, metabolic disorders, and gastrointestinal disorders. Its hepatoprotective, anti-apoptotic, neuroprotective, metabolic, and gastrointestinal effects make it a subject of interest in medical research and clinical practice. Continued research efforts are essential to further elucidate the therapeutic potential, safety profile, and optimal use of TUDCA in various disease conditions and patient populations.